Back to first-pass browser

First-pass extracted concept

ciltacabtagene autoleucel

Candidate: toolkit item2 source documents2 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

cilta-cel

Extracted Explainers

What the tool is doing

Ciltacabtagene autoleucel is a BCMA-directed CAR-T cell product. The abstract states that it has FDA approval for relapsed/refractory multiple myeloma.

Source 1DOIPubMed

Ciltacabtagene autoleucel is named as an example of a BCMA-targeted CAR-T therapy in multiple myeloma. The review places it within a class associated with transformed outcomes in heavily pretreated refractory patients.

Source 2DOIPubMed

Resources required

Use requires the cilta-cel CAR-T product and a BCMA-targeted treatment setting in relapsed/refractory multiple myeloma.

Source 1DOIPubMed

The abstract supports that it is a CAR-T cell therapy, but does not provide operational details.

Source 2DOIPubMed

What problem it solves

It provides an approved cellular immunotherapy option for relapsed/refractory multiple myeloma.

Source 1DOIPubMed

It addresses the need for durable responses in triple-class refractory disease.

Source 2DOIPubMed

What it does not solve

The abstract does not claim that cilta-cel resolves the broader tumor-, patient-, and product-related difficulties of CAR-T therapy.

Source 1DOIPubMed

The abstract does not define its exact place relative to all other sequencing options.

Source 2DOIPubMed

Alternatives

The abstract contrasts cilta-cel with ide-cel and other anti-BCMA products under development.

Source 1DOIPubMed

The review also names idecabtagene vicleucel and discusses anti-CD38 regimens, maintenance therapy, and future bispecific antibodies.

Source 2DOIPubMed

Evidence Snippets

cilta-cel [is a] CAR-T cell[] directed against BCMA, having received approval from the U.S. Food and Drug Administration for relapsed/refractory MM based on the phase 2 ... CARTITUDE trials
Evidence 1Source 1DOIPubMedprovenance
The emergence of B cell maturation antigen (BCMA)-targeted chimeric antigen receptor T (CAR-T) cell therapies, exemplified by idecabtagene vicleucel and ciltacabtagene autoleucel, has transformed outcomes in heavily pretreated, triple-class refractory patients, providing durable responses and quality of life benefits.
Evidence 2Source 2DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1approval statussupports2026Source 1DOIPubMed

Ciltacabtagene autoleucel is an FDA-approved BCMA-directed CAR-T therapy for relapsed/refractory multiple myeloma.

Claim 2review summarysupports2025Source 2DOIPubMed

BCMA-targeted CAR-T cell therapies such as idecabtagene vicleucel and ciltacabtagene autoleucel have transformed outcomes in heavily pretreated, triple-class refractory multiple myeloma and provide durable responses and quality-of-life benefits.